FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * MIDDLETON FRED A   2. Issuer Name and Ticker or Trading Symbol CARDIONET INC [BEAT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 227 WASHINGTON STREET, #300 3. Date of Earliest Transaction (Month/Day/Year) 02/26/2009 (Street) CONSHOHOCKEN, PA 19428 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/26/2009   J(1)   86,021 D $ 0 0 I See Footnote (2) Common Stock 02/26/2009   J(1)   141,857 D $ 0 0 I See Footnote (3) Common Stock 02/26/2009   J(1)   125,245 D $ 0 0 I See Footnote (4) Common Stock 02/26/2009   J(5)   297 A $ 0 243,273 D   Common Stock 02/26/2009   S   330 D $ 26.09 20,322 I See Footnote (6) Common Stock 02/26/2009   S   11 D $ 26.06 20,311 I See Footnote (6) Common Stock 02/26/2009   S   45 D $ 26.05 20,266 I See Footnote (6) Common Stock 02/26/2009   S   48 D $ 26.03 20,218 I See Footnote (6) Common Stock 02/26/2009   S   259 D $ 26.02 19,959 I See Footnote (6) Common Stock 02/26/2009   S   95 D $ 26.01 19,864 I See Footnote (6) Common Stock 02/26/2009   S   875 D $ 26 18,989 I See Footnote (6) Common Stock 02/26/2009   S   236 D $ 25.89 18,753 I See Footnote (6) Common Stock 02/26/2009   S   48 D $ 25.88 18,705 I See Footnote (6) Common Stock 02/26/2009   S   95 D $ 25.87 18,610 I See Footnote (6) Common Stock 02/26/2009   S   109 D $ 25.86 18,501 I See Footnote (6) Common Stock 02/26/2009   S   1,058 D $ 25.85 17,443 I See Footnote (6) Common Stock 02/26/2009   S   142 D $ 25.84 17,301 I See Footnote (6) Common Stock 02/26/2009   S   95 D $ 25.83 17,206 I See Footnote (6) Common Stock 02/26/2009   S   48 D $ 25.82 17,158 I See Footnote (6) Common Stock 02/26/2009   S   377 D $ 25.81 16,781 I See Footnote (6) Common Stock 02/26/2009   S   2,351 D $ 25.8 14,430 I See Footnote (6)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
MIDDLETON FRED A 227 WASHINGTON STREET, #300 CONSHOHOCKEN, PA 19428	X

Signatures

/s/ Catherine A. Petko, by power of attorney		03/02/2009
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Pro rata distribution of shares of common stock to limited partners.
(2)	By Sanderling V Biomedical Co-Investment Fund L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Biomedical Co-Investment Fund L.P and has voting and investment power over the shares held by Sanderling V Biomedical Co-Investment Fund L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
(3)	By Sanderling Venture Partners V Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling Venture Partners V Co-Investment Fund, L.P and has voting and investment power over the shares held by Sanderling Venture Partners V Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
(4)	By Sanderling Venture Partners VI Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil, Mills & Associates VI, LLC the sole general partner of Sanderling Venture Partners VI Co-Investment Fund, L.P and has voting and investment power over the shares held by Sanderling Venture Partners VI Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
(5)	Fred Middleton, a member of the Issuer's board of directors, received a distribution of shares of common stock as a limited partner of the following entities: Sanderling V Biomedical Co-Investment Fund L.P.; Sanderling Venture Partners V Co-Investment Fund, L.P; and Sanderling Venture Partners VI Co-Investment Fund, L.P..
(6)	By Sanderling V Beteilingungs GmbH & Co KG. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Beteilingungs GmbH & Co KG and has voting and investment power over the shares held by Sanderling V Beteilingungs GmbH & Co KG. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.